#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2324	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2482	277.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1916	1916	T	340	T	297	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2324	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2482	277.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1650	1650	C	327	C	270	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3996	289.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1944	1944	A	340	A	279	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3996	289.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2578	2578	C	303	C,A	264,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3996	289.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2652	2652	A	332	A	274	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3866	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3996	289.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3204	3204	C	315	C	266	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	292	folP	855	855	100.0	folP.l15.c4.ctg.1	1766	48.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1161	1163	AGC	57;57;56	A;G;C	48;48;44	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	788	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3711	63.4	1	SNP	p	S91F	1	.	.	271	273	TTC	782	784	TTC	74;73;74	T;T;C,T	54;56;52,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	788	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3711	63.4	1	SNP	p	D95G	1	.	.	283	285	GGC	794	796	GGC	71;72;72	G;G,T;C	59;58,1;55	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	788	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3711	63.4	1	SNP	p	G95N	0	.	.	283	285	GGC	794	796	GGC	71;72;72	G;G,T;C	59;58,1;55	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	340	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1750	58.2	1	SNP	p	G45D	0	.	.	133	135	GGC	666	668	GGC	99;99;99	G;G;C	80;83;81	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	208	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1247	49.5	0	.	n	.	0	A197.	DEL	197	197	A	705	705	A	92	A	79	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	800	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3299	72.4	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1682	1684	GTC	88;88;87	G,C;T;C	70,1;74;75	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	800	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3299	72.4	1	SNP	p	D86N	0	.	.	256	258	GAC	788	790	GAC	93;93;94	G;A,C;C	70;71,4;78	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	800	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3299	72.4	1	SNP	p	S87R	1	.	.	259	261	CGT	791	793	CGT	94;94;94	C;G;T	80;74;71	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	800	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3299	72.4	1	SNP	p	R87I	0	.	.	259	261	CGT	791	793	CGT	94;94;94	C;G;T	80;74;71	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	800	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3299	72.4	1	SNP	p	R87W	0	.	.	259	261	CGT	791	793	CGT	94;94;94	C;G;T	80;74;71	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	800	parC	2304	2304	99.87	parC.l6.c4.ctg.1	3299	72.4	1	SNP	p	S88P	0	.	.	262	264	TCC	794	796	TCC	95;96;97	T;C;C	72;81;77	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3034	59.0	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1542	1544	TGC	67;67;67	T,G;G;C	52,1;51;52	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3034	59.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1752	1754	GGC	72;72;71	G;G;C	56;58;55	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	496	96.59	parE.l6.c4.ctg.2	799	0.0	0	.	p	.	0	G100C	NONSYN	298	300	GGC	308	310	TGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	496	96.59	parE.l6.c4.ctg.2	799	0.0	0	.	p	.	0	F102L	NONSYN	304	306	TTC	314	316	TTA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	496	96.59	parE.l6.c4.ctg.2	799	0.0	0	.	p	.	0	N103K	NONSYN	307	309	AAC	317	319	AAG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	496	96.59	parE.l6.c4.ctg.2	799	0.0	0	.	p	.	0	D106N	NONSYN	316	318	GAC	326	328	AAC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	783	600	parE	1986	496	96.59	parE.l6.c4.ctg.2	799	0.0	0	.	p	.	0	A110fs	FSHIFT	328	328	G	338	338	G	ND	ND	ND	.	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1347	1349	GCA	77;77;78	G;C;A,C	64;63;63,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1350	1352	ATC	78;79;79	A;T;C	64;61;64	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1362	1364	GTG	80;82;83	G;T;G	65;63;67	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1362	1364	GTG	80;82;83	G;T;G	65;63;67	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1866	1868	ACC	54;54;54	A;C;C	47;47;49	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1920	1922	GCG	55;55;55	G;C,G;G	52;45,1;43	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1920	1922	GCG	55;55;55	G;C,G;G	52;45,1;43	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2043	2045	GGC	70;70;70	G;G;C	59;58;59	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2052	2054	GGC	68;68;68	G;G;C,G	59;59;56,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	600	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2626	68.0	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2070	2072	TCG	76;75;75	T,G;C;G	64,1;67;67	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	826	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3397	72.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1736	1738	CCG	56;56;56	C;C;G	43;45;43	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	392	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2291	51.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	873	873	C	63	C	50	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	689	691	GAA	94;96;96	G;A;A	82;84;84	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	977	979	GAT	108;107;107	G,A;A;T,G	87,1;85;86,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1100	1102	TCA	94;94;93	T;C;A	72;78;77	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1229	1231	GTC	88;88;87	G,T;T;C	69,2;74;75	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	0	.	p	.	0	V293A	NONSYN	877	879	GTT	1454	1456	GCT	94;94;95	G;C,A;T	69;72,1;70	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1559	1561	GCA	89;89;90	G;C;A	73;73;76	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	1	SNP	p	G120K	1	.	.	358	360	AAG	935	937	AAG	113;113;110	A;A;G	90;90;86	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	1	SNP	p	D121N	0	.	.	361	363	GAC	938	940	GAC	111;110;110	G;A,C;C	87;87,1;86	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	472	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	2097	66.8	1	SNP	p	A121D	1	.	.	361	363	GAC	938	940	GAC	111;110;110	G;A,C;C	87;87,1;86	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1596	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5192	91.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2252	2254	AAT	88;87;87	A;A;T	78;78;75	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	276	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1234	66.7	1	SNP	p	V57M	1	.	.	169	171	ATG	634	636	ATG	114;115;115	A;T;G	93;92;92	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
